- Home
- WSO vs RPRX Comparison
WSO vs RPRX Comparison
Compare WSO & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WSO | RPRX |
|---|---|---|
| Founded | 1945 | 1996 |
| Country | United States | United States |
| Employees | N/A | 99 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 16.7B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | WSO | RPRX |
|---|---|---|
| Price | $385.71 | $39.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $413.33 | $45.75 |
| AVG Volume (30 Days) | 369.8K | ★ 3.2M |
| Earning Date | 02-17-2026 | 02-11-2026 |
| Dividend Yield | ★ 3.19% | 2.40% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 12.87 | 1.75 |
| Revenue | ★ $7,414,495,000.00 | $2,349,844,000.00 |
| Revenue This Year | N/A | $37.66 |
| Revenue Next Year | $3.52 | $2.34 |
| P/E Ratio | $29.27 | ★ $22.32 |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $323.05 | $29.66 |
| 52 Week High | $535.40 | $41.70 |
Technical Indicators
Market Signals| Indicator | WSO | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 68.76 | 51.97 |
| Support Level | $369.85 | $38.86 |
| Resistance Level | $382.37 | $40.58 |
| Average True Range (ATR) | 11.42 | 0.83 |
| MACD | 3.01 | -0.09 |
| Stochastic Oscillator | 95.39 | 41.20 |
Price Performance
Historical ComparisonAbout WSO Watsco Inc.
Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue), with significant exposure in the Sun Belt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.